Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden

Annals of Surgical Oncology

Volumn 17, Issue 12, 2010, Pages 3314-3323

  Rutkowski, Piotr ^a   Nowecki, Zbigniew I ^a   Van Akkooi, Alexander C J ^b   Kulik, Jadwiga ^a   Wanda, Michej ^a   Siedlecki, Janusz A ^a   Eggermont, Alexander M M ^b   Ruka, Wlodzimierz ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; MICROMETASTASIS; MULTIMARKER REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; OVERALL SURVIVAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SENTINEL LYMPH NODE; SEX DIFFERENCE; TUMOR VOLUME; ULCER;

ADULT; ANTIGENS, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 78650967063     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1142-9     Document Type: Article

References (51)

1. DL Morton JF Thompson AJ Cochran N Mozzillo R Elashoff R Essner, et al. 2006 Sentinel-node biopsy or nodal observation in melanoma N Engl J Med. 355 1307 1317 1:CAS:528:DC%2BD2sXisVaqtr4%3D 10.1056/NEJMoa060992 17005948 (Pubitemid 44465459)
2. JE Gershenwald W Thompson PF Mansfield JE Lee MI Colome CH Tseng, et al. 1999 Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients J Clin Oncol. 17 976 983 1:STN:280:DyaK1M7mvVymsg%3D%3D 10071292
3. MG Statius Muller PA van Leeuwen ES de Lange-De Klerk PJ van Diest R Pijpers CC Ferwerda, et al. 2001 The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma Cancer. 91 2401 2408 1:STN:280:DC%2BD3MzkvFGqsg%3D%3D 10.1002/1097-0142(20010615)91:12<2401::AID-CNCR1274>3.0.CO;2-I 11413531 (Pubitemid 32552828)
4. ZI Nowecki P Rutkowski A Nasierowska-Guttmejer W Ruka 2003 Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes-one institution's experience Melanoma Res. 13 35 43 10.1097/00008390- 200302000-00007 12569283 (Pubitemid 36269812)
5. CM Balch JE Gershenwald S-J Soong JF Thompson MB Atkins DR Byrd, et al. 2009 Final Version of 2009 AJCC Melanoma Staging and Classification J Clin Oncol. 27 6199 6206 10.1200/JCO.2009.23.4799 19917835
6. ZI Nowecki P Rutkowski W Michej 2008 The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3) Ann Surg Oncol 15 2223 2234 10.1245/s10434-008-9965-3 18506535
7. ACJ van Akkooi JHW de Wilt C Verhoef PIM Schmitz AN van Geel AMM Eggermont, et al. 2006 Clinical relevance of melanoma micrometastases (< 0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 17 1578 1585 10.1093/annonc/mdl176 16968875 (Pubitemid 44542045)
8. ACJ van Akkooi ZI Nowecki C Voit G Schafer-Hesterberger W Michej JHW de Wilt, et al. 2008 Sentinel node burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients. A multicenter study in 388 SN positive patients Ann Surg 248 949 955 10.1097/SLA.0b013e31818fefe0 19092339
9. DJ Dewar B Newell MA Green AP Topping BW Powell MG Cook 2004 The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement J Clin Oncol. 22 3345 3349 1:STN:280:DC%2BD2cvgs1GhtQ%3D%3D 10.1200/JCO.2004.12.177 15310779 (Pubitemid 41103692)
10. W Ruka P Rutkowski ZI Nowecki J Kulik A Nasierowska-Guttmejer JA Siedlecki 2004 Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay Ann Surg Oncol. 11 988 997 10.1007/BF02524022
11. ZI Nowecki P Rutkowski J Kulik JA Siedlecki W Ruka 2008 Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level Br J Dermatol. 159 597 605 1:CAS:528:DC%2BD1cXhtF2hsrrI 18616789
12. P Rutkowski ZI Nowecki J Kulik W Ruka JA Siedlecki 2008 Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection Melanoma Res. 18 246 252 1:CAS:528:DC%2BD1cXosFWntbY%3D 10.1097/CMR. 0b013e328307bf3f 18626308
13. CP Karakousis 1998 Therapeutic node dissections in malignant melanoma Semin Surg Oncol. 14 291 301 1:STN:280:DyaK1c3kvVWgtA%3D%3D 10.1002/(SICI)1098- 2388(199806)14:4<291::AID-SSU5>3.0.CO;2-Y 9588722 (Pubitemid 28211038)
14. AMM Eggermont S Suciu R MacKie W Ruka A Testori W Kruit, et al. 2005 Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomized controlled trial Lancet. 366 1189 1196 1:CAS:528:DC%2BD2MXhtVGrsrbL 10.1016/S0140-6736(05)67482-X 16198768 (Pubitemid 41393597)
15. MG Cook MA Green B Anderson AM Eggermont DJ Ruiter A Spatz, et al. 2003 The development of optimal pathological assessment of sentinel lymph nodes for melanoma J Pathol. 200 314 319 10.1002/path.1365 12845627 (Pubitemid 36827305)
16. P Chomczynski N Sacchi 1987 Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal Biochem. 162 156 159 1:CAS:528:DyaL2sXitFSns7Y%3D 10.1016/0003-2697(87)90021-2 2440339
17. I Miyashiro C Kuo K Huynh A Iida D Morton A Bilchik, et al. 2001 Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes Clin Chem. 47 505 512 1:CAS:528:DC%2BD3MXhvVOgtb8%3D 11238304
18. CM Balch SJ Soong JE Gershenwald JF Thompson DS Reintgen N Cascinelli, et al. 2001 Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol. 19 3622 3634 1:STN:280:DC%2BD3MvlvV2ktA%3D%3D 11504744
19. D Berd MJ Mastrangelo T Sato 2005 Calculation of survival of patients with stage III melanoma J Clin Oncol. 23 9427 10.1200/JCO.2005.03.6970 16361644
20. ACJ van Akkooi JHW de Wilt C Verhoef WJ Graveland van Geel M Kliffen, et al. 2006 High positive sentinel node identification rate by EORTC Melanoma Group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma Eur J Cancer. 42 372 380 10.1016/j.ejca.2005.10.023 16403622 (Pubitemid 43132893)
21. A Testori GL De Salvo MC Montesco G Trifirò S Mocellin G Landi, et al. 2009 Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1, 313 patients (SOLISM-IMI) Ann Surg Oncol. 16 2018 2027 10.1245/s10434-008-0273-8 19132446
22. A Testori P Rutkowski J Marsden L Bastholt V Chiarion-Sileni A Hauschild, et al. 2009 Surgery and radiotherapy in the treatment of cutaneous melanoma Ann Oncol 20 Suppl. 6 vi22 vi29 10.1093/annonc/mdp257 19617294
23. CM Balch N Cascinelli 2006 Editorials: Sentinel-node in melanoma N Engl J Med. 355 1370 1372 1:CAS:528:DC%2BD2sXisVGitLw%3D 10.1056/NEJMe068147 17005955 (Pubitemid 44465466)
24. A Doubrovsky JHW de Wilt RA Scolyer WH McCarthy JF Thompson 2004 Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma Ann Surg Oncol. 11 829 836 1:STN:280:DC%2BD2cvjs1Wjsw%3D%3D 10.1245/ASO.2004.01.026 15313732 (Pubitemid 40568810)
25. JE Gershenwald RHI Andtbacka VG Prieto MM Johnson AH Diwan JE Lee, et al. 2008 Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma J Clin Oncol. 26 4296 4303 10.1200/JCO.2007.15.4179 18606982
26. A Govindarajan DM Ghazarian DR McCready WL Leong 2007 Histological features of melanoma sentinel lymph node metatases associated with status of the completion lymphadenectomy and rate of subsequent relapse Ann Surg Oncol. 14 906 912 10.1245/s10434-006-9241-3 17136471 (Pubitemid 46175342)
27. AA Ghaferi SL Wong TM Johnson L Lowe AE Chang VM Cimmino, et al. 2009 Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma Ann Surg Oncol. 16 2978 2984 10.1245/s10434-009-0665-4 19711133
28. JW Jakub M Huebner S Shivers C Nobo C Puleo WS Harmsen, et al. 2009 The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node Ann Surg Oncol. 16 2245 2251 10.1245/s10434-009-0530-5 19517194
29. CT Kuo DS Hoon H Takeuchi R Turner HJ Wang DL Morton, et al. 2003 Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes J Clin Oncol. 21 3566 3572 10.1200/JCO.2003.01.063 12913098 (Pubitemid 46594047)
30. KM McMasters RD Noyes DS Reintgen JS Goydos PD Beitsch BS Davidson, et al. 2004 For The Sunbelt Melanoma Trial. Lessons learned from the Sunbelt Melanoma Trial J Surg Oncol. 86 212 223 10.1002/jso.20084 15221928 (Pubitemid 38880288)
31. S Osella-Abate P Savoia P Quaglino MT Fierro C Leporati M Ortoncelli, et al. 2003 Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: A clinical follow-up study of 110 patients Br J Cancer. 89 1457 1462 1:CAS:528:DC%2BD3sXotFeks7Y%3D 10.1038/sj.bjc.6601197 14562017 (Pubitemid 37386600)
32. S Mocellin DSB Hoon P Pilati CR Rossi D Nitti 2007 Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis J Clin Oncol. 25 1588 1595 10.1200/JCO.2006.09.4573 17443001 (Pubitemid 46733087)
33. JM Hilari C Mangas L Xi C Paradelo C Ferrándiz SJ Hughes, et al. 2009 Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time RT-PCR Ann Surg Oncol. 16 177 185 10.1245/s10434-008-0183-9 18982394
34. C Voit M Kron J Rademaker M Schwürzer-Voit W Sterry L Weber, et al. 2005 Molecular staging in stage II and III melanoma patients and its effect on long-term survival J Clin Oncol. 23 1218 1227 1:CAS:528:DC%2BD2MXitl2gurg%3D 10.1200/JCO.2005.04.098 15718319 (Pubitemid 46202279)
35. CA Voit G Schaefer-Hesterberg M Kron ACJ van Akkooi J Rademaker A Lukowsky, et al. 2008 Impact of molecular staging methods in primary melanoma: Reverse-transcriptase polymerase chain reaction (RT-PCR) of ultrasound-guided aspirate of the sentinel node does not improve diagnostic accuracy, but RT-PCR of peripheral blood does predict survival J Clin Oncol. 26 5742 5747 1:CAS:528:DC%2BD1MXotFemtA%3D%3D 10.1200/JCO.2007.13.7653 18981467
36. G Palmieri PA Ascierto F Perrone SM Satriano A Ottaiano A Daponte, et al. 2003 Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction J Clin Oncol. 21 767 773 1:CAS:528:DC%2BD2cXpsVGru7o%3D 10.1200/JCO.2003.01.128 12610172 (Pubitemid 46606433)
37. CR Scoggins MI Ross DS Reintgen RD Noyes JS Goydos PD Beitsch, et al. 2006 Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma J Clin Oncol. 24 2849 2857 1:CAS:528:DC%2BD28XntV2gsrs%3D 10.1200/JCO.2005.03.2342 16782924 (Pubitemid 46630585)
38. R Micciolo S Boi L Paoli P Cristofolini S Girlando PD Palma, et al. 2009 Clinical relevance of sentinel lymph node status examined with conventional histology and molecular biology Tumori. 95 298 302 19688967
39. C Visús R Andres JI Mayordomo MJ Martinez-Lorenzo L Murillo B Sáez-Gutiérrez, et al. 2007 Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma Melanoma Res. 17 83 89 10.1097/CMR.0b013e3280a60878 17496783 (Pubitemid 46673901)
40. S Steen J Nemunaitis T Fisher J Kuhn 2008 Circulating tumor cells in melanoma: a review of the literature and description of a novel technique Proc (Bayl Univ Med Cent) 21 127 132
41. SC Shivers X Wang W Li E Joseph J Messina LF Glass, et al. 1998 Molecular staging of malignant melanoma: correlation with clinical outcome JAMA. 280 1410 1415 1:STN:280:DyaK1M%2FhsFKiuw%3D%3D 10.1001/jama.280.16.1410 9801000 (Pubitemid 28496047)
42. DS Hoon P Bostick C Kuo T Okamoto HJ Wang R Elashoff, et al. 2000 Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence Cancer Res. 60 2253 2257 1:CAS:528:DC%2BD3cXivVaktr0%3D 10786692
43. H Tsao U Nadiminti AJ Sober M Bigby 2001 A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma Arch Dermatol. 137 325 330 1:CAS:528:DC%2BD3MXisVeqsrY%3D 11255333
44. B Smith P Selby J Southgate K Pittman C Bradley GE Blair 1991 Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction Lancet. 338 1227 1229 1:CAS:528:DyaK38Xit12juro%3D 10.1016/0140-6736(91)92100-G 1719320
45. J Kulik ZI Nowecki P Rutkowski W Ruka M Rochowska H Skurzak, et al. 2001 Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay Melanoma Res. 11 65 73 1:CAS:528:DC%2BD3MXhsFCrsLc%3D 10.1097/00008390-200102000-00008 11254117 (Pubitemid 32158187)
46. J Szenajch B Jasinski A Synowiec J Kulik M Chomicka J Struzyna, et al. 2003 Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma Clin Chem. 49 1450 1457 1:CAS:528:DC%2BD3sXmvVertLs%3D 10.1373/49.9.1450 12928225 (Pubitemid 37011732)
47. J Szenajch B Jasinski A Kozak J Kulik M Chomicka J Struzyna, et al. 2002 Multiple RT-PCR tyrosinase testing reveals that melanoma cells circulate in the blood of melanoma patients at the frequency more than 10 times below the detection threshold Melanoma Res. 12 399 401 1:STN:280:DC%2BD38vhsVGktw%3D%3D 10.1097/00008390-200208000-00014 12170191 (Pubitemid 34816447)
48. U Keilholz P Goldin-Lang NE Bechrakis N Max A Letsch A Schmittel, et al. 2004 Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction Clin Cancer Res. 10 1605 1612 1:CAS:528:DC%2BD2cXhvFClsbw%3D 10.1158/1078-0432.CCR-0610-3 15014010 (Pubitemid 38435549)
49. BJ Curry K Myers P Hersey 1999 MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases J Clin Oncol. 17 2562 2571 1:STN:280: DC%2BD3c%2FjtVSmsA%3D%3D 10561323
50. B Schittek Y Bodingbauer U Ellwanger HJ Blaheta C Garbe 1999 Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma Br J Dermatol. 141 30 36 1:CAS:528:DyaK1MXlsFGht70%3D 10.1046/j.1365-2133.1999.02917.x 10417512 (Pubitemid 29333690)
51. I Miyashiro C Kuo K Huynh A Iida D Morton A Bilchik, et al. 2001 Molecular Strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A Genes Clin Chem. 47 505 512 1:CAS:528:DC%2BD3MXhvVOgtb8%3D